Aktiespot

Damora Therapeutics, Inc. aksje

DMRA

After-hours
$22.33-0.62 (-2.70%)
Post-Market:$22.69+0.36 (+1.61%)
Laster graf...

Damora Therapeutics, Inc.

Åpning23.15
Høy23.28
Lav22.13
Volum317.8k
P/EN/A
Markedsverdi1.37B
52-ukers høy38.33
52-ukers lav2.45
Gj.sn. volum304.83k
UtbytteN/A
Beta1.51
EPS-2.68

Om Damora Therapeutics, Inc. aksje

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Selskapsinformasjon

Børs: NasdaqCM (NCM)
Sektor: Sundhed
Industri: Bioteknologi
Adresse:
Building 23
02453 Waltham, United States
Telefon: + 781 281 9020

Analytikernes aksjeanbefalinger

Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.

Anbefaling:1.14 - Stærk køb
Laveste kursmål
35.00
56.7%
Gjennomsnittlig kursmål
43.14
93.2%
Median kursmål
45.00
101.5%
Høyeste kursmål
51.00
128.4%

Andre ser også på: